Mirae Asset Global Investments Co., Ltd. Neurocrine Biosciences Inc Transaction History

Mirae Asset Global Investments Co., Ltd.

$20 Billion
Q2 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,832 shares of NBIX stock, worth $459,265. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,832

Previous 13,300 71.19%

Holding current value

$459,265

Previous $1.83 Million 71.26%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	SELL	$130.86 - $143.19 $1.24 Million - $1.36 Million	-9,468 Reduced 71.19%	3,832 $527,000
Q1 2024 May 01, 2024	SELL	$130.4 - $143.74 $1.78 Million - $1.97 Million	-13,688 Reduced 50.72%	13,300 $1.83 Million
Q4 2023 Jan 24, 2024	SELL	$106.07 - $132.76 $219,989 - $275,344	-2,074 Reduced 7.14%	26,988 $3.56 Million
Q3 2023 Oct 26, 2023	SELL	$94.02 - $117.1 $611,318 - $761,384	-6,502 Reduced 18.28%	29,062 $3.27 Million
Q2 2023 Aug 10, 2023	SELL	$89.53 - $104.87 $333,857 - $391,060	-3,729 Reduced 9.49%	35,564 $3.35 Million
Q1 2023 May 04, 2023	BUY	$94.11 - $123.02 $1.19 Million - $1.56 Million	12,663 Added 47.55%	39,293 $3.98 Million
Q4 2022 Feb 09, 2023	SELL	$106.72 - $127.06 $628,474 - $748,256	-5,889 Reduced 18.11%	26,630 $3.18 Million
Q3 2022 Nov 10, 2022	SELL	$92.03 - $107.81 $424,534 - $497,327	-4,613 Reduced 12.42%	32,519 $3.39 Million
Q2 2022 Jul 26, 2022	SELL	$75.79 - $100.07 $99,284 - $131,091	-1,310 Reduced 3.41%	37,132 $3.62 Million
Q1 2022 May 10, 2022	SELL	$72.45 - $94.81 $366,886 - $480,117	-5,064 Reduced 11.64%	38,442 $3.61 Million
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $213,541 - $284,775	-2,681 Reduced 5.8%	43,506 $3.69 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $486,227 - $558,727	5,642 Added 13.92%	46,187 $4.43 Million
Q2 2021 Aug 11, 2021	SELL	$89.43 - $102.27 $98,820 - $113,008	-1,105 Reduced 2.65%	40,545 $3.95 Million
Q1 2021 May 13, 2021	SELL	$87.57 - $119.4 $849,866 - $1.16 Million	-9,705 Reduced 18.9%	41,650 $4.05 Million
Q4 2020 Feb 10, 2021	BUY	$86.91 - $108.33 $1.02 Million - $1.27 Million	11,726 Added 29.59%	51,355 $4.92 Million
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $114,045 - $160,287	1,186 Added 3.09%	39,629 $3.83 Million
Q2 2020 Aug 11, 2020	SELL	$85.09 - $130.36 $664,212 - $1.02 Million	-7,806 Reduced 16.88%	38,443 $4.69 Million
Q1 2020 May 12, 2020	SELL	$75.11 - $113.76 $14.5 Million - $22 Million	-193,081 Reduced 80.68%	46,249 $4 Million
Q4 2019 Feb 12, 2020	SELL	$86.8 - $118.57 $568,887 - $777,107	-6,554 Reduced 2.67%	239,330 $25.7 Million
Q3 2019 Nov 12, 2019	SELL	$83.82 - $101.5 $4.75 Million - $5.75 Million	-56,650 Reduced 18.73%	245,884 $22.2 Million
Q2 2019 Aug 13, 2019	SELL	$72.24 - $91.27 $274,439 - $346,734	-3,799 Reduced 1.24%	302,534 $25.5 Million
Q1 2019 May 13, 2019	BUY	$69.31 - $91.53 $2.81 Million - $3.71 Million	40,572 Added 15.27%	306,333 $27 Million
Q4 2018 Feb 11, 2019	BUY	$68.32 - $124.36 $1.08 Million - $1.97 Million	15,861 Added 6.35%	265,761 $19 Million
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $16.2 Million - $20.7 Million	164,306 Added 191.96%	249,900 $30.7 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $399,240 - $561,958	5,302 Added 6.6%	85,594 $8.41 Million
Q1 2018 May 10, 2018	BUY	$75.88 - $92.43 $2.04 Million - $2.49 Million	26,930 Added 50.47%	80,292 $6.66 Million
Q4 2017 Feb 12, 2018	BUY	$58.53 - $77.59 $2.21 Million - $2.92 Million	37,690 Added 240.49%	53,362 $4.14 Million
Q3 2017 Nov 08, 2017	BUY	$47.97 - $61.28 $751,785 - $960,380	15,672	15,672 $961,000

Others Institutions Holding NBIX

# of Institutions

641

Shares Held

95.3M

Call Options Held

661K

Put Options Held

227K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Neurocrine Biosciences Inc Transaction History